Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Eccles

Showing results (231-240 of 240) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 240 results.
Journal of Medicinal Chemistry|February 14, 2015
Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screenAurélie Mallinger, Simon Crumpler, Mark Pichowicz, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|July 21, 2009
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperonePaul A Brough, Xavier Barril, Jenifer Borgognoni, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Breast Cancer Research : BCR|November 30, 2013
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancerSuzanne A Eccles, Eric O Aboagye, Simak Ali, et al.
Nature Communications|November 2, 2019
Associations of autozygosity with a broad range of human phenotypesDavid W Clark, Yukinori Okada, Kristjan H S Moore, et al.
Pageof 24

Showing results (231-240 of 240) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 240 results.
Journal of Medicinal Chemistry|February 14, 2015
Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screenAurélie Mallinger, Simon Crumpler, Mark Pichowicz, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|July 21, 2009
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperonePaul A Brough, Xavier Barril, Jenifer Borgognoni, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Breast Cancer Research : BCR|November 30, 2013
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancerSuzanne A Eccles, Eric O Aboagye, Simak Ali, et al.
Nature Communications|November 2, 2019
Associations of autozygosity with a broad range of human phenotypesDavid W Clark, Yukinori Okada, Kristjan H S Moore, et al.
Pageof 24